Netramark Signs Contract with a Leading Global Biopharmaceutical Company to Enhance Clinical Trial Insights

Executive Summary

• NetraMark Holdings Inc. signed a new contract with an unnamed leading biopharmaceutical company to apply its NetraAI platform to a Phase 3 clinical trial of a novel psychiatric medicine.
• The engagement expands NetraMark’s portfolio of AI‑driven projects in neuroscience, oncology and complex pain, demonstrating continued industry adoption of its explainable AI technology.
• CEO George Achilleos highlighted that the partnership reflects growing recognition that NetraMark’s platform can improve trial success rates by identifying patient subpopulations linked to treatment response, placebo response and adverse events.

Key Details

• Contract Scope: Deployment of NetraAI’s proprietary AI methodology to analyze multidimensional clinical data from a Phase 3 psychiatric trial, generating explainable subpopulation insights for regulatory and market‑access strategies.
• Technology Highlights:
• Dynamical systems framework enabling effective analysis of small, complex datasets.
• Focus mechanisms that separate “explainable” vs. “unexplainable” patient subsets to avoid over‑fitting and improve insight quality.
• Strategic Impact: Adds a high‑profile biopharma client, reinforcing NetraMark’s positioning as a next‑generation AI provider for precision clinical trial analytics.
• Sector Coverage: Extends the company’s work in neuroscience, oncology, and complex pain, indicating broader applicability of its platform across therapeutic areas.
• Leadership Quote: “This project reflects the growing recognition among biopharmaceutical companies that NetraMark’s explainable AI can improve the chance of trial success,” – George Achilleos, CEO.

Notable Quotes

“NetraAI aims to provide clear, scientifically and clinically interpretable outputs that sponsors can act on — helping them to understand precisely who benefits most, why, and how to design their next pivotal studies with greater confidence.” – George Achilleos, CEO, NetraMark Holdings Inc.